SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator: Cbdpotential, djmurdock
Search This Board: 
Last Post: 7/28/2017 1:34:02 AM - Followers: 54 - Board type: Free - Posts Today: 1


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

ZYNE
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE News: Biotech Players Lead the Growth Charge in the Legal Cannabis Market 07/27/2017 08:45:00 AM
ZYNE News: Potential Blockbuster Treatment for Alzheimer’s Disease Stands Out Among Medical Cannabis Companies 07/25/2017 08:45:00 AM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 07/06/2017 04:03:06 PM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 07/06/2017 04:02:38 PM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 07/06/2017 04:02:10 PM
News News Alert: Biotech Players Lead the Growth Charge in the Legal Cannabis Market 07/27/2017 08:45:00 AM
PostSubject
#326  Sticky Note Slideshow for new investors djmurdock 12/17/16 05:09:50 PM
#678   Very frustrating. Either some bad news leaked or djmurdock 07/28/17 01:34:02 AM
#677   It's the entire market, which is even scarier. MoToM 07/27/17 04:54:36 PM
#676   What the F is going on here this Bescaredxx 07/27/17 03:56:07 PM
#675   I was thinking $57. Don't let these MM WolfOfGrnStreet 07/26/17 07:47:54 PM
#674   I was thinking $27. surfgreen 07/26/17 07:18:06 PM
#673   Looks like bottom to me. Load up for TinyGreenSprout 07/26/17 03:54:56 PM
#672   Really needs to hold the 16.90 level for a surfer 07/26/17 03:26:18 PM
#671   We should be bottoming out at $17, a djmurdock 07/26/17 01:38:29 PM
#670   It's currently my biggest position so I hear djmurdock 07/25/17 02:10:45 PM
#669   Could not agree more! Exept im seriously anoyed Bescaredxx 07/25/17 01:40:08 PM
#668   Interesting how they always drop this in the djmurdock 07/25/17 12:27:03 PM
#667   Run up is imminent! djmurdock 07/24/17 02:33:02 PM
#666   August is approaching. This is gonna explode on surfgreen 07/24/17 12:01:52 PM
#665   Feeling optimistic about this one :-D $ZYNE Patience And Perspective Cbdpotential 07/23/17 03:03:50 AM
#664   Just wait. The term patience is a virtue. WolfOfGrnStreet 07/22/17 12:37:43 AM
#663   Still a little concerned about this not being Bescaredxx 07/21/17 11:13:19 PM
#662   Biotech Bellwethers levered to cannabis ----> https://technical420.com/cannabis- SBPartners 07/20/17 07:31:30 AM
#661   Although I was wrongly confident in the CARA djmurdock 07/19/17 06:51:02 PM
#660   Im fine with them coming out end of a surfer 07/19/17 05:27:31 PM
#659   Results could be out any day but they djmurdock 07/18/17 12:46:04 PM
#658   news may be due any time now! why Bescaredxx 07/18/17 08:07:40 AM
#657   You bet it is! With such a low CoachMarc 07/17/17 03:47:05 AM
#656   Storm is a brewin here. WolfOfGrnStreet 07/14/17 01:51:27 PM
#655   This 19.12 19.35 and 19.60 are resistance...after a surfer 07/14/17 11:34:56 AM
#654   Yep. 60-75 is my range. This company doesn't WolfOfGrnStreet 07/13/17 11:13:50 PM
#653   Yeah I totally disagree on these projections. I'm djmurdock 07/13/17 03:55:47 PM
#652   Holy Smokes! $4-$75 pps based on star trial surfgreen 07/13/17 02:54:26 PM
#651   http://thefly.com/landingPageNews.php?id=2575332&headline=ZYNE-Zynerba-shares-co djmurdock 07/13/17 12:13:59 PM
#650   Such BS. They will never let this breathe. djmurdock 07/13/17 12:01:59 PM
#649   Here comes $ZYNE. To the 20, to the WolfOfGrnStreet 07/12/17 09:11:42 PM
#648   I am a lot more confident in their djmurdock 07/12/17 01:56:35 PM
#647   Looks like $$ pouring in for the July surfgreen 07/12/17 01:43:31 PM
#646   Hoping this is the start to the July djmurdock 07/12/17 12:29:17 PM
#645   8.50 and what it's at now is going WolfOfGrnStreet 07/11/17 07:19:13 PM
#644   ...CARA's phase 2 OA trial had nothing to seppi08162 07/11/17 04:30:37 PM
#642   Tons of mj news on the way.. good cattbell1952 07/05/17 08:39:11 AM
#641   Hmm, care to explain what you mean? thanks! goin2buy 07/04/17 10:07:47 PM
#640   It's going to get very hot in MJ cattbell1952 07/04/17 08:18:07 PM
#639   All about ZYN002 now focus2011 07/03/17 03:45:50 PM
#638   That sucks. Hoping ZYNE will have better results. surfgreen 06/30/17 01:48:59 PM
#637   Considering zyne and cara are currently my biggest djmurdock 06/30/17 11:30:10 AM
#636   Brutal...riding off CARA coattails? a surfer 06/30/17 09:53:30 AM
#635   Will they ever let these breathe? From +7% djmurdock 06/27/17 01:17:54 PM
#634   whats the story is it a buy out? madmanmartinwins 06/27/17 11:59:57 AM
#633   And on the Russel 3000 djmurdock 06/26/17 08:46:08 PM
#632   Making power moves, phase 2 coming quick! djmurdock 06/26/17 08:43:24 PM
#631   Probably keep getting manipulated in this range till djmurdock 06/26/17 01:00:16 PM
#630   $ZYNE$ Fuel the rockets for takeoff surfgreen 06/26/17 08:53:42 AM
#629   This stock is so easy to manipulate and djmurdock 06/22/17 01:47:18 PM
#628   Yep. All 7 analysts on NASDAQ rate this LoveItInBishop 06/19/17 06:04:19 PM
PostSubject